Aggregation of amyloid β-protein as function of age and apolipoprotein E in normal and Alzheimer's serum

Journal of the Neurological Sciences

Volumn 154, Issue 2, 1998, Pages 159-163

  Chauhan, Abha ^a   Pirttilä, Tuula ^b   Chauhan, Ved P S ^a   Mehta, Pankaj ^a   Wisniewski, Henryk M ^a  

^a NEW YORK STATE INSTITUTE FOR BASIC RESEARCH IN DEVELOPMENTAL DISABILITIES   (United States)

^b TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

Author keywords

Aging; Alzheimer's disease; Amyloid protein; Apolipoprotein E; Serum

Indexed keywords

AMYLOID; AMYLOID BETA PROTEIN; APOLIPOPROTEIN E;

ADULT; AGED; AGING; ALBUMIN BLOOD LEVEL; ALLELE; ALZHEIMER DISEASE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DEMENTIA; DISEASE SEVERITY; HUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN AGGREGATION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; AGING; ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; ANALYSIS OF VARIANCE; APOLIPOPROTEINS E; CASE-CONTROL STUDIES; HUMANS; MIDDLE AGED; PHENOTYPE;

EID: 0032485034     PISSN: 0022510X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-510X(97)00221-9     Document Type: Article

References (30)

1. 1-antichymotrypsin in the brain amyloid deposits of Alzheimer's disease. Cell. 52:1988;487-501.
2. Brousseau T., Legraine S., Berr C., Gourlet V., Vidal O., Amoyel P. Confirmation of the E4 allele of the apolipoprotein E gene as a risk factor for late-onset Alzheimer's disease. Neurology. 44:1994;342-344.
3. Carlsson J., Armstrong V.W., Reiber H., Felgenhauer K., Seidel D. Clinical relevance of the quantitation of apolipoprotein E in cerebrospinal fluid. Clin. Chim. Acta. 196:1991;167-176.
4. Chauhan A., Pirttilä T., Mehta P., Chauhan V.P.S., Wisniewski H.M. Effect of cerebrospinal fluid from normal and Alzheimer's patients with different apolipoprotein E phenotypes on in vitro aggregation of amyloid beta-protein. J. Neurol. Sci. 141:1996;54-58.
5. Corder E.H., Saunders A.M., Strittmatter W.J., Schmechel D.E., Gaskell P.C., Small G.W., Roses A.D., Haines J.L., Pericak-Vance M.A. Gene dose of apolipoprotein E type 4 and the risk of Alzheimer's disease in late onset families. Science. 261:1993;921-923.
6. Coria F., Castano E.M., Prelli F., Larrondo-Lillo M., VanDuinen S., Shelanski M.L., Frangione B. Isolation and characterization of amyloid P component from Alzheimer's disease and other types of cerebral amyloidosis. Lab. Invest. 58:1988;454-457.
7. Goldgaber D., Schwarzman A.I., Bhasin R., Gregori L., Schmechel D., Saunders A.M., Roses A.D., Strittmatter W.J. Sequestration of amyloid β-peptide. Ann. NY Acad. Sci. 695:1993;139-143.
8. Haass C., Schlossmacher M.G., Hung A.Y., Vigo-Pelfrey C., Mellon A., Ostaszewski B.L., Lieberburg I., Koo E.H., Schenk D., Teplow D.B., Selkoe D.J. Amyloid beta-peptide is produced by cultured cells during normal metabolism. Nature. 359:1992;322-325.
9. Itzhaki R.F. Possible factors in the etiology of Alzheimer's Disease. Mol. Neurobiol. 9:1994;1-13.
10. Jamieson G.A., Maitland N.J., Wilcock G.K., Yates C.M., Itzhaki R.F. Herpes simplex virus type 1 DNA is present in specific regions of brain from aged people with and without senile dementia of the Alzheimer type. J. Pathol. 167:1992;365-368.
11. LaDu M.J., Falduto M.T., Manelli A.M., Reardon C.A., Getz G.S., Frail D.E. Isoform-specific binding of apolipoprotein E to β-amyloid. J. Biol. Chem. 269:1994;23403-23406.
12. Lehtimaki T., Moilanen T., Viikari J., Akerblom H.K., Ehnholm C., Ronnemaa T., Marniemi J., Dahlen G., Nikkari T. Apolipoprotein E phenotypes in Finnish youths: a cross-sectional and 6-year follow up study. J. Lipid Res. 31:1990;487-495.
13. Lehtimaki T., Pirttilä T., Mehta P.D., Wisniewski H.M., Frey H., Nikkari T. Apolipoprotein E (apo E) polymorphism and its influence on apo E concentrations in the cerebrospinal fluid in Finnish patients with Alzheimer's disease. Hum. Genet. 95:1995;39-42.
14. LeVine H. Soluble multimeric Alzheimer β (1-40) preamyloid complexes in dilute solution. Neurobiol. Aging. 16:1995;755-764.
15. Liddell M., Williams J., Bayer A., Kaiser F., Owen P. Confirmation of association between the ε4 allele of apolipoprotein E and Alzheimer's disease. J. Med. Genet. 31:1994;197-200.
16. 1-antichymotrypsin and apolipoprotein E promote assembly of Alzheimer β-protein into filament. Nature. 372:1994;92-94.
17. Masters C.L., Simms G., Weiman N.A., McDonald B.L., Beyreuther K. Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proc. Natl. Acad. Sci. USA. 82:1985;4245-4249.
18. McKhann G., Drachman D., Folstein M., Katzman R., Price D., Stadlan E.M. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 34:1984;939-944.
19. Naiki H., Higuchi K., Hosokawa M., Takeda T. Fluorometric determination of amyloid fibrils in vitro using the fluorescent dye, Thioflavine T. Anal. Biochem. 177:1989;244-249.
20. Poirier J., Davignon J., Bouthillier D., Kogan S., Bertrand P., Gauthier S. Apolipoprotein E polymorphism and Alzheimer's disease. Lancet. 342:1993;697-699.
21. Saunders A.M., Strittmatter W.J., Schmechel D., St. George-Hyslop P.H., Pericak-Vance M.A., Joo S.H., Rosi B.L., Gusella J.F., Crapper-MacLachlan D.R., Alberts M.J., Hulette C., Crain B., Goldgaber D., Roses A.D. Association of apolipoprotein E allele ε4 with late-onset familial and sporadic Alzheimer's disease. Neurology. 43:1993;1467-1472.
22. Schmechel D.E., Saunders A.M., Strittmatter W.J., Crain B.J., Hulette C.M., Joo S.H., Pericak-Vance M.A., Goldgaber D., Roses A.D. Increased amyloid β-protein deposition in cerebral cortex as a consequence of apolipoprotein E genotype in late-onset Alzheimer disease. Proc. Natl. Acad. Sci. USA. 90:1993;9649-9653.
23. Schwarzman A.L., Gregori L., Vitek M.P., Lyubski S., Strittmatter W.J., Enghilde J.J., Bhasin R., Silverman J., Weisgraber K.H., Coyle P.K., Zagorski M.G., Talafous J., Eisenberg M., Saunders A.M., Roses A.D., Goldgaber D. Transthyretin sequesters amyloid β-protein and prevents amyloid formation. Proc. Natl. Acad. Sci. USA. 91:1994;8368-8372.
24. Seubert P., Vigo-Pelfrey C., Esch F., Lee M., Dovey H., Davis D., Sinha S., Schlossmacher M., Whaley J., Swindlehyurst C., McCormack R., Wolfert R., Selkoe D., Lieberburg I., Schenk D. Isolation and quantitation of soluble Alzheimer's beta-peptide from biological fluids. Nature. 359:1992;325-327.
25. Strittmatter W.J., Weisgraber K.H., Huang D.Y., Dong L.M., Salvessen G.S., Pericak-Vance M., Schmechel D., Saunders A.M., Goldgaber D., Roses A.D. Binding of human apolipoprotein E to synthetic amyloid β peptide: Isoform-specific effects and implications for late onset Alzheimer disease. Proc. Natl. Acad. Sci. USA. 90:1993;8098-8102.
26. Su J.H., Cummings B.J., Cotman C.W. Localization of heparan sulfate glycosaminoglycan and proteoglycan core protein in aged brain and Alzheimer's disease. Neuroscience. 51:1992;801-813.
27. Wisniewski, H.M., Mehta, P.D., Kim, K.S., Merz, G.S., 1989. Cerebrospinal fluid-based laboratory test for Alzheimer's disease. In: Boller et al. (Eds.), Biological Markers of Alzheimer's Disease. Springer-Verlag, Berlin/Heidelberg, pp. 23-29.
28. Wisniewski T., Castano E.M., Golabek A., Vogel T., Frangione B. Acceleration of Alzheimer's fibril formation by apolipoprotein E in vitro. Am. J. Pathol. 145:1994;1030-1035.
29. Wisniewski T., Ghiso J., Frangione B. Alzheimer's disease and soluble Aβ Neurobiol. Aging. 15:1994;143-152.
30. Wisniewski H.M., Frackowiak J., Mazur-Kolecka B. In vitro production of β-amyloid in smooth muscle cells isolated from amyloid angiopathy-affected vessels. Neurosci. Lett. 183:1995;120-123.